Relapsing-remitting Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Relapsing-remitting Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-02-20Clinical Trial Update: Mitochondrial Dysfunction and Disease Progression
A completed clinical trial (NCT02549703) examining the role of mitochondrial dysfunction in disease progression across multiple sclerosis fo…
-
CLINICAL_TRIALS trial_result · 2019-02-12Clinical Trial Update: Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants
An observational study evaluating natalizumab (Tysabri) in early relapsing-remitting multiple sclerosis patients who are anti-JC virus antib…
-
CLINICAL_TRIALS trial_result · 2019-02-08Clinical Trial Update: Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01) [Phase 4]
Phase 4 follow-up study of fingolimod in relapsing-remitting multiple sclerosis; results from the original biobank study were posted.
-
CLINICAL_TRIALS trial_result · 2019-02-06Clinical Trial Update: Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis [Phase 1]
Phase 1 trial update reporting completion of helminth-induced immunomodulation therapy (HINT) in Relapsing-remitting multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2019-01-25Clinical Trial Update: Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy [Phase 4]
Phase 4 clinical trial update comparing Fingolimod efficacy in de novo Relapsing-Remitting Multiple Sclerosis patients versus those previous…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-12-07Clinical Trial Update: Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis [Phase 4]
Phase 4 clinical trial evaluating alemtuzumab on MRI surrogate markers of disease activity and repair in relapsing remitting multiple sclero…
-
CLINICAL_TRIALS trial_result · 2018-11-21Clinical Trial Update: TMP001 in Relapsing-remitting Multiple Sclerosis [Phase 2]
Phase 2 clinical trial of TMP001 in relapsing-remitting multiple sclerosis has been completed.
-
CLINICAL_TRIALS trial_result · 2018-11-20Clinical Trial Update: An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) [Phase 3]
Phase 3 trial update of BG00012 (Dimethyl Fumarate) in Asian subjects with relapsing-remitting multiple sclerosis (RRMS) has completed.
-
CLINICAL_TRIALS trial_result · 2018-11-15Clinical Trial Update: A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) [Phase 2]
Phase 2 clinical trial update for relapsing-remitting multiple sclerosis completed with results posted.
-
CLINICAL_TRIALS trial_result · 2018-11-09Clinical Trial Update: Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis [Phase 2]
A Phase 2 extension study evaluating safety and efficacy of daclizumab high yield process (BIIB019) in participants with relapsing-remitting…
-
CLINICAL_TRIALS trial_result · 2018-10-16Clinical Trial Update: Advanced MRI Measures of Repair in Alemtuzumab Treated Patients [Phase 3]
Phase 3 trial update reporting advanced MRI measures of repair in alemtuzumab-treated patients with relapsing-remitting multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2018-10-09Clinical Trial Update: A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo [Phase 3]
Phase 3 trial evaluating glatiramer acetate 40 mg three times weekly versus placebo in relapsing-remitting multiple sclerosis completed with…
-
CLINICAL_TRIALS trial_result · 2018-06-27Clinical Trial Update: Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis [Phase 4]
Phase 4 trial comparing Rebif (interferon beta-1a) with Copaxone (glatiramer acetate) in relapsing-remitting multiple sclerosis; results hav…
-
CLINICAL_TRIALS trial_result · 2018-05-04Clinical Trial Update: Ireland Natalizumab (TYSABRI) Observational Program
This clinical trial update notes the completion of an observational program in Ireland evaluating Natalizumab (TYSABRI) for Relapsing-Remitt…
-
CLINICAL_TRIALS trial_result · 2018-05-03Clinical Trial Update: Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Hispanics With RRMS
An exploratory, completed clinical trial evaluating the clinical response to fingolimod (Gilenya) in Hispanic patients with relapsing-remitt…
-
CLINICAL_TRIALS trial_result · 2018-04-05Clinical Trial Update: Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy [Phase 4]
Phase 4 clinical trial evaluating whether Vitamin K can reduce redness at injection sites in participants with relapsing-remitting multiple …
-
CLINICAL_TRIALS trial_result · 2018-03-20Clinical Trial Update: Flupirtine as Oral Treatment in Multiple Sclerosis [Phase 2]
Phase 2 clinical trial evaluating Flupirtine as an oral treatment for Relapsing-Remitting Multiple Sclerosis was terminated.
-
CLINICAL_TRIALS trial_result · 2018-03-20Clinical Trial Update: Atorvastatin in Relapsing-Remitting Multiple Sclerosis [Phase 2]
A Phase 2 trial testing atorvastatin for relapsing-remitting multiple sclerosis has completed.
-
CLINICAL_TRIALS trial_result · 2018-03-01Clinical Trial Update: Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis [Phase 2]
Phase 2 trial evaluating subcutaneous ofatumumab in relapsing-remitting multiple sclerosis has completed and posted results.
-
CLINICAL_TRIALS trial_result · 2018-03-01Clinical Trial Update: Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®
This study reports real-world clinical, neurological, tolerability, and safety outcomes for Tecfidera (dimethyl fumarate) and Rebif (interfe…
-
CLINICAL_TRIALS trial_result · 2018-02-28Clinical Trial Update: This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for ≤ 3 Years [Phase 2]
A Phase 2 randomized study comparing two oral doses of INT131 (1 mg and 3 mg daily) versus placebo in treatment-naïve relapsing-remitting mu…
-
CLINICAL_TRIALS trial_result · 2017-12-12Clinical Trial Update: Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis [Phase 2]
This Phase 2 study reports long-term safety, tolerability, and efficacy data for orally administered BAF312 (siponimod) in patients with Rel…
-
CLINICAL_TRIALS trial_result · 2017-11-17Clinical Trial Update: A Pilot Study of Intermittent Calorie Restriction in Multiple Sclerosis [NA]
A pilot clinical trial update evaluating intermittent calorie restriction as a potential intervention for Relapsing Remitting Multiple Scler…
-
CLINICAL_TRIALS trial_result · 2017-11-17Clinical Trial Update: Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis
This update reports the completion of an Optical Coherence Tomography (OCT) trial in patients with Relapsing-remitting multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2017-11-07Clinical Trial Update: BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon
The BETAEVAL Global study evaluates adherence to Betaferon therapy in relapsing-remitting multiple sclerosis patients using the BETACONNECT …